TORL BioTherapeutics
PrivateLast Round
Series C
Oct 7, 2025
Total Funding Raised
$461.9M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
TORL BioTherapeutics is a biopharmaceutical company that develops antibody-drug conjugates and monoclonal antibodies for the treatment of various cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
TORL BioTherapeutics Comparables
Compare TORL BioTherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Gilead Sciences | 87% | |
| Sutro Biopharma Inc | 80% | |
| Genmab A/S | 79% |
For institutional investors. Book with your work email.
TORL BioTherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Oct 7, 2025 | ||||
| Series B Extension | Apr 10, 2024 | ||||
| Series B | Apr 13, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
TORL BioTherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RA Capital Management | Series B Extension |
| Vertex Ventures HC | Series B, Series B Extension |
| Perceptive Advisors | Series B, Series B Extension |
| Xontogeny | Series B, Series B Extension |
| TD Securities | Series B |
| Blue Owl Capital | Series B, Series B Extension |
| Deep Track Capital | Series B, Series B Extension |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors grew 83% MoM, reaching 6.8K.
- Oct 7, 2025
$96M round completed.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresOct 16, 2026
TORL BioTherapeutics, LLC. hires Eric Sievers, who brings more than three decades of oncology clinical research and antibody-drug conjugate development experience to support the company’s growth and lead candidate, ixotatug vedotin.
- hiresOct 16, 2026
TORL BioTherapeutics, LLC. appoints Eric Sievers, M.D., as Chief Medical Officer in California on Oct 16th '26, strengthening its executive leadership as it advances antibody-based cancer therapies toward late-stage clinical development and potential commercialization.
- hiresOct 16, 2026
TORL BioTherapeutics, LLC. appoints Sandip Kapadia as Chief Financial Officer in California on Oct 16th '26, expanding its executive leadership as it advances antibody-based cancer therapies toward late-stage clinical development and potential commercialization.
For institutional investors. Book with your work email.
TORL BioTherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about TORL BioTherapeutics's valuation, stock price, and market status.
Is TORL BioTherapeutics a public or private company?
TORL BioTherapeutics is a private company.
What is the current stock price of TORL BioTherapeutics?
TORL BioTherapeutics is a private company, so its shares have no public market price. Caplight tracks TORL BioTherapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is TORL BioTherapeutics worth (valuation)?
Valuation information for TORL BioTherapeutics is not publicly available.
Can I buy TORL BioTherapeutics stock?
TORL BioTherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was TORL BioTherapeutics's last funding round?
TORL BioTherapeutics's most recent funding round was Series C on October 7, 2025.
Who are the main investors in TORL BioTherapeutics?
Key investors in TORL BioTherapeutics include Deep Track Capital, Goldman Sachs Asset Management Private Equity, Goldman Sachs Asset Management.
Will TORL BioTherapeutics IPO soon?
No public IPO plans have been announced for TORL BioTherapeutics.
How can I track TORL BioTherapeutics secondary market activity?
Caplight tracks bids, offers, and trades in TORL BioTherapeutics's shares on secondary markets.